Kala Bio Inc.
KALA
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.9M
Close$
$0.93
58.6% downside
Current Fair Value
58.6% downsideOvervalued by 58.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.90 Million |
|---|---|
| Enterprise Value | $47.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.31 |
| Beta | -2.24 |
| Outstanding Shares | 8,148,275 |
Return
| Return on Equity | -167.58% |
|---|---|
| Return on Assets | -146.40% |
| Return on Invested Capital | -316.52% |
Valuation & Multiples
| P/E Ratio | -0.92 |
|---|---|
| PEG | 0.92 |
| Price to Sales | - |
| Price to Book Ratio | 2.24 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.38 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-8.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-6.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.86%▼ 19.47% |
|---|---|
| Total Invested | $293,931▼ 81.39% |
| Investors Holding | 26▼ 2.00% |
ESG Score
No data
About Kala Pharmaceuticals Inc
CEO: Mark Iwicki